A randomized discontinuation phase II study of sorafenib vs placebo in patients with non-small cell lung cancer (NSCLC) who failed at least two prior chemotherapy regimens: E2501 Schiller, J., Lee, J., Hanna, N. H., Traynor, A. M., Wakelee, H., Carbone, D. P. LIPPINCOTT WILLIAMS & WILKINS. 2009: S355–S356

View details for Web of Science ID 000269496001086